Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry.


Journal

Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937

Informations de publication

Date de publication:
16 08 2022
Historique:
received: 27 06 2022
accepted: 01 08 2022
entrez: 16 8 2022
pubmed: 17 8 2022
medline: 19 8 2022
Statut: epublish

Résumé

Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by pathogenic TP53 variants. The condition represents one of the most relevant genetic causes of cancer in children and adults due to its frequency and high cancer risk. The term Li-Fraumeni spectrum reflects the evolving phenotypic variability of the condition. Within this spectrum, patients who meet specific LFS criteria are diagnosed with LFS, while patients who do not meet these criteria are diagnosed with attenuated LFS. To explore genotype-phenotype correlations we analyzed 141 individuals from 94 families with pathogenic TP53 variants registered in the German Cancer Predisposition Syndrome Registry. Twenty-one (22%) families had attenuated LFS and 73 (78%) families met the criteria of LFS. NULL variants occurred in 32 (44%) families with LFS and in two (9.5%) families with attenuated LFS (P value < 0.01). Kato partially functional variants were present in 10 out of 53 (19%) families without childhood cancer except adrenocortical carcinoma (ACC) versus 0 out of 41 families with childhood cancer other than ACC alone (P value < 0.01). Our study suggests genotype-phenotype correlations encouraging further analyses.

Identifiants

pubmed: 35974385
doi: 10.1186/s13045-022-01332-1
pii: 10.1186/s13045-022-01332-1
pmc: PMC9382737
doi:

Substances chimiques

Tumor Suppressor Protein p53 0

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107

Subventions

Organisme : BMBF ADDRess
ID : 01GM1909E
Organisme : BMBF ADDRess
ID : 01GM1909D
Organisme : BMBF ADDRess
ID : 01GM1909A
Organisme : Deutsche Kinderkrebsstiftung
ID : DKS2019.13

Informations de copyright

© 2022. The Author(s).

Références

Science. 1990 Nov 30;250(4985):1233-8
pubmed: 1978757
J Natl Cancer Inst. 1969 Dec;43(6):1365-73
pubmed: 5396222
Mol Cancer Res. 2011 Mar;9(3):271-9
pubmed: 21343334
Cancer Res. 1988 Sep 15;48(18):5358-62
pubmed: 3409256
Cancer Genet. 2020 Oct;248-249:11-17
pubmed: 32966936
J Clin Oncol. 2015 Jul 20;33(21):2345-52
pubmed: 26014290
Carcinogenesis. 2007 Feb;28(2):289-98
pubmed: 16861262
Nat Genet. 2018 Oct;50(10):1381-1387
pubmed: 30224644
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9
pubmed: 12826609
Hum Mutat. 2021 Mar;42(3):223-236
pubmed: 33300245
Mol Cell. 2018 Sep 6;71(5):873
pubmed: 30193102
Genet Med. 2019 Nov;21(11):2478-2484
pubmed: 31105275
JAMA Oncol. 2021 Dec 01;7(12):1800-1805
pubmed: 34709361

Auteurs

Judith Penkert (J)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.
Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Farina J Strüwe (FJ)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Christina M Dutzmann (CM)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Beate B Doergeloh (BB)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Emilie Montellier (E)

Univ. Grenoble Alpes, Inserm 1209, CNRS 5309, Institute for Advanced Biosciences, F38000, Grenoble, France.

Claire Freycon (C)

Univ. Grenoble Alpes, Inserm 1209, CNRS 5309, Institute for Advanced Biosciences, F38000, Grenoble, France.
Department of Pediatrics, Grenoble Alpes University Hospital, Grenoble, France.

Myriam Keymling (M)

Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Heinz-Peter Schlemmer (HP)

Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Birte Sänger (B)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Beatrice Hoffmann (B)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Tanja Gerasimov (T)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Claudia Blattmann (C)

Department of Pediatric Oncology, Hematology and Immunology, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany.

Sebastian Fetscher (S)

Department of Haematology and Oncology, Sana Hospitals, Lübeck, Germany.

Michael Frühwald (M)

Paediatric and Adolescent Medicine, University Medical Center Augsburg, Augsburg, Germany.

Simone Hettmer (S)

Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Uwe Kordes (U)

Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Vita Ridola (V)

Department of Pediatric Oncology and Hematology, MITERA Children's Hospital, Athens, Greece.

Sabine Kroiss Benninger (S)

Department of Oncology, University Children's Hospital Zürich, Zurich, Switzerland.

Angela Mastronuzzi (A)

Department of Haematology, Oncology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.

Sarah Schott (S)

Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.

Juliane Nees (J)

Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.

Aram Prokop (A)

Department of Pediatric Hematology/Oncology, Helios Clinic Schwerin, Schwerin, Germany.
Medical School Hamburg (MSH), University of Applied Sciences and Medical University, Hamburg, Germany.
Department of Pediatric Hematology and Oncology, Children's Hospital, Cologne, Germany.

Antje Redlich (A)

Pediatric Oncology Department, Otto von Guericke University Children's Hospital, Magdeburg, Germany.

Markus G Seidel (MG)

Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.

Stefanie Zimmermann (S)

Pediatric Hematology and Oncology, University Hospital, Frankfurt, Germany.

Kristian W Pajtler (KW)

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Stefan M Pfister (SM)

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Pierre Hainaut (P)

Univ. Grenoble Alpes, Inserm 1209, CNRS 5309, Institute for Advanced Biosciences, F38000, Grenoble, France.

Christian P Kratz (CP)

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany. kratz.christian@mh-hannover.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH